<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21165295</article-id><article-id pub-id-type="pmc">2995234</article-id><article-id pub-id-type="doi">10.3346/jkms.2010.25.12.1784</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Gastroenterology &amp; Hepatology</subject></subj-group></subj-group></article-categories><title-group><article-title>Effect of Probiotic <italic>Lactobacillus</italic> (Lacidofil® Cap) for the Prevention of Antibiotic-associated Diarrhea: A Prospective, Randomized, Double-blind, Multicenter Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Song</surname><given-names>Hyun Joo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jin-Yong</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jung</surname><given-names>Sung-Ae</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seong-Eun</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Hye-Sook</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Yoolwon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Sung Pil</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cheon</surname><given-names>Jae Hee</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Won Ho</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyo-Jong</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Byong Duk</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Suk-Kyun</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sang-Woo</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Sung-Jae</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyun-Soo</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sung</surname><given-names>Jae-Kyu</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Eun Young</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Internal Medicine and Preventive Medicine, Ewha Womans University School of Medicine, Seoul, Korea.</aff><aff id="A2"><label>2</label>Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff><aff id="A3"><label>3</label>Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</aff><aff id="A4"><label>4</label>Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea.</aff><aff id="A5"><label>5</label>Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.</aff><aff id="A6"><label>6</label>Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.</aff><aff id="A7"><label>7</label>Department of Internal Medicine, Ajou University College of Medicine, Suwon, Korea.</aff><aff id="A8"><label>8</label>Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.</aff><aff id="A9"><label>9</label>Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.</aff><aff id="A10"><label>10</label>Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.</aff><author-notes><fn id="FN1" fn-type="equal"><p><sup>*</sup>Hyun Joo Song and Jin-Yong Kim contributed equally to this work.</p></fn><corresp>
Address for Correspondence: Sung-Ae Jung, M.D. Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 204 Anyangcheon-gil, Yangcheon-gu, Seoul 158-710, Korea. Tel: +82.2-2650-5053, Fax: +82.2-2655-2076, <email>jassa@ewha.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>24</day><month>11</month><year>2010</year></pub-date><volume>25</volume><issue>12</issue><fpage>1784</fpage><lpage>1791</lpage><history><date date-type="received"><day>12</day><month>6</month><year>2010</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2010</year></date></history><permissions><copyright-statement>© 2010 The Korean Academy of Medical Sciences.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="6734" xml_f="6884" txt_i="11" txt_f="161">Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. There is growing interest in probiotics for the treatment of AAD and </offsets><italic><offsets xml_i="6892" xml_f="6913" txt_i="161" txt_f="182">Clostridium difficile</offsets></italic><offsets xml_i="6922" xml_f="7101" txt_i="182" txt_f="361"> infection because of the wide availability of probiotics. The aim of this multicenter, randomized, placebo-controlled, double-blind trial was to assess the efficacy of probiotic </offsets><italic><offsets xml_i="7109" xml_f="7122" txt_i="361" txt_f="374">Lactobacillus</offsets></italic><offsets xml_i="7131" xml_f="7344" txt_i="374" txt_f="587"> (Lacidofil® cap) for the prevention of AAD in adults. From September 2008 to November 2009, a total of 214 patients with respiratory tract infection who had begun receiving antibiotics were randomized to receive </offsets><italic><offsets xml_i="7352" xml_f="7365" txt_i="587" txt_f="600">Lactobacillus</offsets></italic><offsets xml_i="7374" xml_f="7639" txt_i="600" txt_f="865"> (Lacidofil® cap) or placebo for 14 days. Patients recorded bowel frequency and stool consistency daily for 14 days. The primary outcome was the proportion of patients who developed AAD within 14 days of enrollment. AAD developed in 4 (3.9%) of 103 patients in the </offsets><italic><offsets xml_i="7647" xml_f="7660" txt_i="865" txt_f="878">Lactobacillus</offsets></italic><offsets xml_i="7669" xml_f="7730" txt_i="878" txt_f="939"> group and in 8 (7.2%) of 111 patients in the placebo group (</offsets><italic><offsets xml_i="7738" xml_f="7739" txt_i="939" txt_f="940">P</offsets></italic><offsets xml_i="7748" xml_f="7769" txt_i="940" txt_f="961">=0.44). However, the </offsets><italic><offsets xml_i="7777" xml_f="7790" txt_i="961" txt_f="974">Lactobacillus</offsets></italic><offsets xml_i="7799" xml_f="7917" txt_i="974" txt_f="1092"> group showed lower change in bowel frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) (</offsets><italic><offsets xml_i="7925" xml_f="7926" txt_i="1092" txt_f="1093">P</offsets></italic><offsets xml_i="7935" xml_f="8100" txt_i="1093" txt_f="1258">=0.01). Although the Lacidofil® cap does not reduce the rate of occurrence of AAD in adult patients with respiratory tract infection who have taken antibiotics, the </offsets><italic><offsets xml_i="8108" xml_f="8121" txt_i="1258" txt_f="1271">Lactobacillus</offsets></italic><offsets xml_i="8130" xml_f="8209" txt_i="1271" txt_f="1350"> group maintains their bowel habits to a greater extent than the placebo group.</offsets></p></abstract><kwd-group><kwd>Probiotics</kwd><kwd><italic>Lactobacillus</italic></kwd><kwd>Antibiotic-associated Diarrhea</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="8408" xml_f="8420" txt_i="1358" txt_f="1370">INTRODUCTION</offsets></title><p><offsets xml_i="8431" xml_f="8711" txt_i="1371" txt_f="1651">Antibiotic-associated diarrhea (AAD) is emerging as a common complication of antibiotic use. The frequency of AAD can be high (26-60%) during hospital outbreaks or intermediate (13-29%) during endemic periods and is relatively low in outpatient settings (usually less than 0.1%) (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8742" xml_f="8743" txt_i="1651" txt_f="1652">1</offsets></xref><offsets xml_i="8750" xml_f="8752" txt_i="1652" txt_f="1654">, </offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8783" xml_f="8784" txt_i="1654" txt_f="1655">2</offsets></xref><offsets xml_i="8791" xml_f="8988" txt_i="1655" txt_f="1852">). Risk factors for AAD include the use of broad-spectrum antibiotics, various host factors (old age, poor general condition), a longer hospitalization period and exposure to nosocomial pathogens (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="9019" xml_f="9020" txt_i="1852" txt_f="1853">1</offsets></xref><offsets xml_i="9027" xml_f="9028" txt_i="1853" txt_f="1854">-</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9059" xml_f="9060" txt_i="1854" txt_f="1855">3</offsets></xref><offsets xml_i="9067" xml_f="9286" txt_i="1855" txt_f="2074">). AAD can occur 2 to 8 weeks after exposure to antibiotics as a result of disruption of intestinal microflora. One of the main roles of normal gut microflora is to protect against colonization by intestinal pathogens (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9317" xml_f="9318" txt_i="2074" txt_f="2075">4</offsets></xref><offsets xml_i="9325" xml_f="9488" txt_i="2075" txt_f="2238">). Once this protective barrier is broken, patients are more susceptible to infection with opportunistic pathogens. Probiotics have been proposed to treat AAD and </offsets><italic><offsets xml_i="9496" xml_f="9517" txt_i="2238" txt_f="2259">Clostridium difficile</offsets></italic><offsets xml_i="9526" xml_f="9699" txt_i="2259" txt_f="2432"> disease. Probiotics mainly assist in re-establishing the disrupted intestinal microflora, enhancing immune responses and clearing pathogens and their toxins from the host (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9730" xml_f="9731" txt_i="2432" txt_f="2433">5</offsets></xref><offsets xml_i="9738" xml_f="9739" txt_i="2433" txt_f="2434">-</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9770" xml_f="9771" txt_i="2434" txt_f="2435">7</offsets></xref><offsets xml_i="9778" xml_f="9780" txt_i="2435" txt_f="2437">).</offsets></p><p><offsets xml_i="9787" xml_f="9856" txt_i="2438" txt_f="2507">There is growing interest in probiotics for the treatment of AAD and </offsets><italic><offsets xml_i="9864" xml_f="9876" txt_i="2507" txt_f="2519">C. difficile</offsets></italic><offsets xml_i="9885" xml_f="10008" txt_i="2519" txt_f="2642"> disease because of the wide availability of probiotics as dietary supplements and concern over recent outbreaks of severe </offsets><italic><offsets xml_i="10016" xml_f="10028" txt_i="2642" txt_f="2654">C. difficile</offsets></italic><offsets xml_i="10037" xml_f="10080" txt_i="2654" txt_f="2697"> disease in Canada and the United Kingdom (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10111" xml_f="10112" txt_i="2697" txt_f="2698">8</offsets></xref><offsets xml_i="10119" xml_f="10121" txt_i="2698" txt_f="2700">, </offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="10152" xml_f="10153" txt_i="2700" txt_f="2701">9</offsets></xref><offsets xml_i="10160" xml_f="10395" txt_i="2701" txt_f="2936">). Research on probiotics has been reported for the past 28 yr (1977-2005), but the studies have been variable in trial design, type of probiotic and dosage and duration of treatment, and thus have often yielded contradictory results (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10427" xml_f="10429" txt_i="2936" txt_f="2938">10</offsets></xref><offsets xml_i="10436" xml_f="10575" txt_i="2938" txt_f="3077">). Twenty-five randomized, controlled trials (RCTs) provided adequate data regarding the efficacy of probiotics for the prevention of AAD (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10607" xml_f="10609" txt_i="3077" txt_f="3079">10</offsets></xref><offsets xml_i="10616" xml_f="10651" txt_i="3079" txt_f="3114">). Of the 25 RCTs, only 6 utilized </offsets><italic><offsets xml_i="10659" xml_f="10682" txt_i="3114" txt_f="3137">Lactobacillus rhamnosus</offsets></italic><offsets xml_i="10691" xml_f="10693" txt_i="3137" txt_f="3139"> (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10725" xml_f="10727" txt_i="3139" txt_f="3141">11</offsets></xref><offsets xml_i="10734" xml_f="10735" txt_i="3141" txt_f="3142">-</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="10767" xml_f="10769" txt_i="3142" txt_f="3144">16</offsets></xref><offsets xml_i="10776" xml_f="10778" txt_i="3144" txt_f="3146">).</offsets></p><p><offsets xml_i="10785" xml_f="10835" txt_i="3147" txt_f="3197">There were a few RCTs that proved the efficacy of </offsets><italic><offsets xml_i="10843" xml_f="10856" txt_i="3197" txt_f="3210">Lactobacillus</offsets></italic><offsets xml_i="10865" xml_f="10957" txt_i="3210" txt_f="3302"> in preventing AAD, and debate arose regarding the study populations. A study on the use of </offsets><italic><offsets xml_i="10965" xml_f="10977" txt_i="3302" txt_f="3314">L. rhamnosus</offsets></italic><offsets xml_i="10986" xml_f="10992" txt_i="3314" txt_f="3320"> (2×10</offsets><sup><offsets xml_i="10997" xml_f="10999" txt_i="3320" txt_f="3322">10</offsets></sup><offsets xml_i="11005" xml_f="11130" txt_i="3322" txt_f="3447"> colonforming units per day) for preventing AAD in 302 adults receiving antibiotics at the Mayo Clinic showed no efficacy of </offsets><italic><offsets xml_i="11138" xml_f="11150" txt_i="3447" txt_f="3459">L. rhamnosus</offsets></italic><offsets xml_i="11159" xml_f="11310" txt_i="3459" txt_f="3610"> in decreasing the overall incidence of AAD because quite a few patients had stool cultures, additional tests for diarrhea, or a positive diagnosis of </offsets><italic><offsets xml_i="11318" xml_f="11330" txt_i="3610" txt_f="3622">C. difficile</offsets></italic><offsets xml_i="11339" xml_f="11341" txt_i="3622" txt_f="3624"> (</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="11373" xml_f="11375" txt_i="3624" txt_f="3626">15</offsets></xref><offsets xml_i="11382" xml_f="11455" txt_i="3626" txt_f="3699">). However, 89 patients in a recent RCT on the daily administration of a </offsets><italic><offsets xml_i="11463" xml_f="11476" txt_i="3699" txt_f="3712">Lactobacillus</offsets></italic><offsets xml_i="11485" xml_f="11572" txt_i="3712" txt_f="3799">fermented milk product showed that it was safe and effective in the prevention of AAD (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11604" xml_f="11606" txt_i="3799" txt_f="3801">17</offsets></xref><offsets xml_i="11613" xml_f="11682" txt_i="3801" txt_f="3870">). A recent RCT involving 135 patients demonstrated that a probiotic </offsets><italic><offsets xml_i="11690" xml_f="11703" txt_i="3870" txt_f="3883">Lactobacillus</offsets></italic><offsets xml_i="11712" xml_f="11743" txt_i="3883" txt_f="3914"> preparation prevented AAD and </offsets><italic><offsets xml_i="11751" xml_f="11763" txt_i="3914" txt_f="3926">C. difficile</offsets></italic><offsets xml_i="11772" xml_f="11794" txt_i="3926" txt_f="3948">-associated diarrhea (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="11826" xml_f="11828" txt_i="3948" txt_f="3950">18</offsets></xref><offsets xml_i="11835" xml_f="11837" txt_i="3950" txt_f="3952">).</offsets></p><p><offsets xml_i="11844" xml_f="11970" txt_i="3953" txt_f="4079">Therefore, we conducted a multicenter, randomized, placebo-controlled, double-blind trial to assess the efficacy of probiotic </offsets><italic><offsets xml_i="11978" xml_f="11991" txt_i="4079" txt_f="4092">Lactobacillus</offsets></italic><offsets xml_i="12000" xml_f="12061" txt_i="4092" txt_f="4153"> (Lacidofil® cap) for the prevention of AAD in Korean adults.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="12112" xml_f="12133" txt_i="4155" txt_f="4176">MATERIALS AND METHODS</offsets></title><sec><title><offsets xml_i="12153" xml_f="12165" txt_i="4177" txt_f="4189">Participants</offsets></title><p><offsets xml_i="12176" xml_f="12541" txt_i="4190" txt_f="4552">Adult patients receiving antibiotic therapy for respiratory tract infection were screened at 10 tertiary hospitals. The inclusion criteria were adult inpatients aged &gt;18 yr who received oral or injected antibiotics for respiratory tract infections within 48 hr of enrollment. The following patients were excluded from the study: 1) those who were diagnosed with </offsets><italic><offsets xml_i="12549" xml_f="12561" txt_i="4552" txt_f="4564">C. difficile</offsets></italic><offsets xml_i="12570" xml_f="13587" txt_i="4564" txt_f="5581"> colitis within the previous 3 months, 2) those who were given tube feeding or who underwent an ileostomy or colostomy, 3) those with basal diarrheal disease (acute enteritis, inflammatory bowel disease, radiation enteritis, ischemic colitis and diarrhea caused by carcinoid), 4) those receiving other probiotics during the previous 15 days, 5) those treated with immunosuppressant drugs and those with immune deficiency, 6) those who underwent radiotherapy or chemotherapy treatment for cancer, 7) those treated with antidiarrheal, antispasmodic or motility agents for other diseases, 8) pregnant or lactating women, 9) those who underwent gastrointestinal surgery 3 months prior to the study, 10) those with a history of hypersensitivity to cephalosporins, penicillin or clavulanic acid, 11) those with verified diabetic autonomic neuropathy, 12) those who underwent organ transplantations, and 13) those with underlying conditions or diseases who, in the opinion of the investigator, were unsuitable for inclusion.</offsets></p></sec><sec><title><offsets xml_i="13609" xml_f="13621" txt_i="5583" txt_f="5595">Study design</offsets></title><p><offsets xml_i="13632" xml_f="13803" txt_i="5596" txt_f="5767">Between September 2008 and November 2009, a total of 214 patients with respiratory tract infection who had begun to receive antibiotics were randomly allocated to receive </offsets><italic><offsets xml_i="13811" xml_f="13824" txt_i="5767" txt_f="5780">Lactobacillus</offsets></italic><offsets xml_i="13833" xml_f="14307" txt_i="5780" txt_f="6254"> (Lacidofil® cap) or a placebo for 14 days. This study was conducted at 10 investigational centers. Participants recorded their bowel frequency and stool consistency every day for 14 days. The primary outcome (AAD-1) was defined as loose or watery stools more than 3 times per day for at least 2 days within 14 days of enrollment. The secondary outcome (AAD-2) was defined as loose or watery stools more than 2 times per day for at least 2 days within 14 days of enrollment.</offsets></p><p><offsets xml_i="14314" xml_f="14711" txt_i="6255" txt_f="6652">The admitting medical team identified eligible patients who had an antibiotic prescription for the treatment of respiratory tract infection. After the investigators obtained informed consent, they collected baseline data and prescribed the study drug on a randomized basis. The hospital pharmacy dispensed the drug. The treatment group received a probiotic preparation (Lacidofil® cap) containing </offsets><italic><offsets xml_i="14719" xml_f="14731" txt_i="6652" txt_f="6664">L. rhamnosus</offsets></italic><offsets xml_i="14740" xml_f="14747" txt_i="6664" txt_f="6671"> R0011·</offsets><italic><offsets xml_i="14755" xml_f="14769" txt_i="6671" txt_f="6685">L. acidophilus</offsets></italic><offsets xml_i="14778" xml_f="14808" txt_i="6685" txt_f="6715"> R0052 bacterial culture (2×10</offsets><sup><offsets xml_i="14813" xml_f="14814" txt_i="6715" txt_f="6716">9</offsets></sup><offsets xml_i="14820" xml_f="15638" txt_i="6716" txt_f="7534"> colony-forming units), maltodextrin, Mg stearate, and ascorbic acid. The control group received a placebo drug composed of maltodextrin, Mg stearate and ascorbic acid. Participants began using the Lacidofil® cap or placebo drug within 48 hr of initiation of antibiotic therapy. The Lacidofil® cap and placebo were administrated at a dose of 1 capsule twice a day for 14 days. The administration of other drugs for accompanying diseases permitted subject to the investigator's judgment. The use of antidiarrheal (e.g., loperamide, polypcarbophil), antispasmodic (e.g., tiropramide, pinaverium, buscopan) or motility agents (e.g., domperidone, mosapride, itopride, levosulpride) that could affect the symptoms was prohibited. These drugs were withheld until the patient developed AAD, after which their use was allowed.</offsets></p><p><offsets xml_i="15645" xml_f="15963" txt_i="7535" txt_f="7853">Investigators followed up participants for 14 days to check stool frequency, stool consistency and compliance. If participants had AAD, investigators collected further data on clinical symptoms and blood test results. As the safety of Lacidofil® cap has already been proven, its safety was not evaluated in this study.</offsets></p></sec><sec><title><offsets xml_i="15985" xml_f="15996" txt_i="7855" txt_f="7866">Sample size</offsets></title><p><offsets xml_i="16007" xml_f="16329" txt_i="7867" txt_f="8189">We estimated that the minimum sample size was 220 for each group. The sample size was calculated on the basis of an 18% difference in the proportion of AAD compared with the control group with an expected compliance rate of 80%, a statistical power (two sided) of 90%, a significance level of 5% and a dropout rate of 10%.</offsets></p></sec><sec><title><offsets xml_i="16351" xml_f="16384" txt_i="8191" txt_f="8224">Randomization and double blinding</offsets></title><p><offsets xml_i="16395" xml_f="17037" txt_i="8225" txt_f="8867">Among patients with respiratory tract infection, those who met the inclusion criteria were selected and allocated trial numbers. The subjects were allocated to the treatment (Lacidofil® cap treatment) or control groups (placebo) according to their trial numbers. To maintain double-blinding, the envelope containing the random trial number allocation code was sealed by the investigators, and the treatment allocations were not disclosed until the clinical trial was completed, except for cases for which access to the code was necessary. All investigators, participants, outcome assessors and data analysts were blinded throughout the study.</offsets></p></sec><sec><title><offsets xml_i="17059" xml_f="17079" txt_i="8869" txt_f="8889">Statistical analysis</offsets></title><p><offsets xml_i="17090" xml_f="17557" txt_i="8890" txt_f="9357">SPSS for Windows software (V. 13.0, SPSS, Chicago, IL, USA) was used for statistical analysis. The chi-square test was used to determine the difference in the incidence of AAD between the 2 groups, and the Student's t-test was used for analysis of continuous variables. Multiple logistic regression analysis was used to identify the risk factors for AAD, and effect estimates are presented as the odds ratio (OR) and 95% confidence interval (CI). For all analyses, a </offsets><italic><offsets xml_i="17565" xml_f="17566" txt_i="9357" txt_f="9358">P</offsets></italic><offsets xml_i="17575" xml_f="17637" txt_i="9358" txt_f="9420"> value of 0.05 or less (two sided) was considered significant.</offsets></p></sec><sec><title><offsets xml_i="17659" xml_f="17675" txt_i="9422" txt_f="9438">Ethics statement</offsets></title><p><offsets xml_i="17686" xml_f="17883" txt_i="9439" txt_f="9636">The Institutional Review Board (IRB) of each hospital approved the study protocol (Ewha Womans University Mokdong Hospital, IRB No. 187-17). Written informed consent was obtained from each patient.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="17930" xml_f="17937" txt_i="9639" txt_f="9646">RESULTS</offsets></title><sec><title><offsets xml_i="17957" xml_f="18018" txt_i="9647" txt_f="9708">Participant flow and baseline characteristics of participants</offsets></title><p><offsets xml_i="18029" xml_f="18059" txt_i="9709" txt_f="9739">Patient flow is summarized in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="18089" xml_f="18095" txt_i="9739" txt_f="9745">Fig. 1</offsets></xref><offsets xml_i="18102" xml_f="18859" txt_i="9745" txt_f="10502">. Over the 14-month study period, 286 patients were screened as potential candidates for this study by nurses. Of the 286 patients screened, 18 met 1 or more of the exclusion criteria, 28 did not meet all of the inclusion criteria, and 26 refused to participate in the study. Of the 214 patients who met the inclusion criteria and agreed to participate in the study, 42 failed to complete the study. Finally, 172 patients completed the study. Of the 42 patients who failed to complete the study, 5 had adverse events, 12 received contraindicated drugs, 21 did not continue the treatment protocol, and 4 were lost to follow-up. We performed intention-to-treat (ITT) analysis of data from 214 patients and per-protocol (PP) analysis of data from 172 patients.</offsets></p><p><offsets xml_i="18866" xml_f="18909" txt_i="10503" txt_f="10546">Baseline characteristics are summarized in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="18941" xml_f="18948" txt_i="10546" txt_f="10553">Table 1</offsets></xref><offsets xml_i="18955" xml_f="18985" txt_i="10553" txt_f="10583">. The placebo (n=111) and the </offsets><italic><offsets xml_i="18993" xml_f="19006" txt_i="10583" txt_f="10596">Lactobacillus</offsets></italic><offsets xml_i="19015" xml_f="19454" txt_i="10596" txt_f="11035"> groups (n=103) were similar in terms of their demographics and medical profiles at enrollment. There were no significant differences in total dose of antibiotics, baseline bowel movement, drug compliance, or pulmonary infections between the 2 groups. Respiratory tract infections, in descending order of frequency, were pneumonia, pulmonary tuberculosis, bronchitis, bronchiectasis, pleural effusion and upper respiratory tract infection.</offsets></p><p><offsets xml_i="19461" xml_f="19509" txt_i="11036" txt_f="11084">Antibiotic use for both groups is summarized in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="19541" xml_f="19548" txt_i="11084" txt_f="11091">Table 2</offsets></xref><offsets xml_i="19555" xml_f="19812" txt_i="11091" txt_f="11348">. The antibiotics used were, in descending order, cephalosporin, macrolides, fluoroquniolones, antituberculosis drugs, clindamycin and penicillin. β-lactam antibiotics, including cephalosporins and penicillin, were commonly used in both the placebo and the </offsets><italic><offsets xml_i="19820" xml_f="19833" txt_i="11348" txt_f="11361">Lactobacillus</offsets></italic><offsets xml_i="19842" xml_f="19868" txt_i="11361" txt_f="11387"> groups (75.7% vs 78.6%) (</offsets><italic><offsets xml_i="19876" xml_f="19877" txt_i="11387" txt_f="11388">P</offsets></italic><offsets xml_i="19886" xml_f="19971" txt_i="11388" txt_f="11473">=0.72). There were no significant differences in antibiotic use between the 2 groups.</offsets></p></sec><sec><title><offsets xml_i="19993" xml_f="20021" txt_i="11475" txt_f="11503">Analysis of outcome measures</offsets></title><p><offsets xml_i="20032" xml_f="20108" txt_i="11504" txt_f="11580">In ITT analysis (n=214), AAD-1 developed in 4 (3.9%) of 103 patients in the </offsets><italic><offsets xml_i="20116" xml_f="20129" txt_i="11580" txt_f="11593">Lactobacillus</offsets></italic><offsets xml_i="20138" xml_f="20199" txt_i="11593" txt_f="11654"> group and in 8 (7.2%) of 111 patients in the placebo group (</offsets><italic><offsets xml_i="20207" xml_f="20208" txt_i="11654" txt_f="11655">P</offsets></italic><offsets xml_i="20217" xml_f="20276" txt_i="11655" txt_f="11714">=0.44). AAD-2 developed in 9 (8.7%) of 103 patients in the </offsets><italic><offsets xml_i="20284" xml_f="20297" txt_i="11714" txt_f="11727">Lactobacillus</offsets></italic><offsets xml_i="20306" xml_f="20369" txt_i="11727" txt_f="11790"> group and in 16 (14.4%) of 111 patients in the placebo group (</offsets><italic><offsets xml_i="20377" xml_f="20378" txt_i="11790" txt_f="11791">P</offsets></italic><offsets xml_i="20387" xml_f="20576" txt_i="11791" txt_f="11980">=0.28). There was no significant difference in AAD occurrence between the 2 groups. However, no changes in bowel frequency or consistency were reported by 50 (48.5%) of 103 patients in the </offsets><italic><offsets xml_i="20584" xml_f="20597" txt_i="11980" txt_f="11993">Lactobacillus</offsets></italic><offsets xml_i="20606" xml_f="20669" txt_i="11993" txt_f="12056"> group and by 35 (31.5%) of 111 patients in the placebo group (</offsets><italic><offsets xml_i="20677" xml_f="20678" txt_i="12056" txt_f="12057">P</offsets></italic><offsets xml_i="20687" xml_f="20882" txt_i="12057" txt_f="12252">=0.01). Increased bowel frequency over a period of more than 3 days during the 14-day period was observed in 47 (42.3%) of 111 patients in the placebo group and 31 (30.1%) of 103 patients in the </offsets><italic><offsets xml_i="20890" xml_f="20903" txt_i="12252" txt_f="12265">Lactobacillus</offsets></italic><offsets xml_i="20912" xml_f="20920" txt_i="12265" txt_f="12273"> group (</offsets><italic><offsets xml_i="20928" xml_f="20929" txt_i="12273" txt_f="12274">P</offsets></italic><offsets xml_i="20938" xml_f="20946" txt_i="12274" txt_f="12282">=0.08) (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="20978" xml_f="20985" txt_i="12282" txt_f="12289">Table 3</offsets></xref><offsets xml_i="20992" xml_f="21045" txt_i="12289" txt_f="12342">). The results of multivariate analysis of the OR of </offsets><italic><offsets xml_i="21053" xml_f="21066" txt_i="12342" txt_f="12355">Lactobacillus</offsets></italic><offsets xml_i="21075" xml_f="21153" txt_i="12355" txt_f="12433"> for AAD-1, AAD-2, and change in bowel frequency and consistency are shown in </offsets><xref ref-type="table" rid="T4"><offsets xml_i="21185" xml_f="21192" txt_i="12433" txt_f="12440">Table 4</offsets></xref><offsets xml_i="21199" xml_f="21205" txt_i="12440" txt_f="12446">. The </offsets><italic><offsets xml_i="21213" xml_f="21226" txt_i="12446" txt_f="12459">Lactobacillus</offsets></italic><offsets xml_i="21235" xml_f="21551" txt_i="12459" txt_f="12775"> group was less likely to experience changes in bowel frequency and consistency compared with the placebo group (OR 0.43, 95% CI 0.25-0.82), which means that although Lacidofil® cap does not reduce the rate of occurrence rate of AAD in adult patients with respiratory tract infection who have taken antibiotics, the </offsets><italic><offsets xml_i="21559" xml_f="21572" txt_i="12775" txt_f="12788">Lactobacillus</offsets></italic><offsets xml_i="21581" xml_f="21661" txt_i="12788" txt_f="12868"> group maintained their bowel habits to a greater extent than the placebo group.</offsets></p><p><offsets xml_i="21668" xml_f="21781" txt_i="12869" txt_f="12982">In PP analysis (n=172, excluding 42 patients who dropped out), AAD-1 developed in 3 (3.6%) of 83 patients in the </offsets><italic><offsets xml_i="21789" xml_f="21802" txt_i="12982" txt_f="12995">Lactobacillus</offsets></italic><offsets xml_i="21811" xml_f="21871" txt_i="12995" txt_f="13055"> group and in 5 (5.6%) of 89 patients in the placebo group (</offsets><italic><offsets xml_i="21879" xml_f="21880" txt_i="13055" txt_f="13056">P</offsets></italic><offsets xml_i="21889" xml_f="21948" txt_i="13056" txt_f="13115">=0.72). AAD-2 developed in 8 (9.6%) of 103 patients in the </offsets><italic><offsets xml_i="21956" xml_f="21969" txt_i="13115" txt_f="13128">Lactobacillus</offsets></italic><offsets xml_i="21978" xml_f="22039" txt_i="13128" txt_f="13189"> group and in 9 (10.1%) of 89 patients in the placebo group (</offsets><italic><offsets xml_i="22047" xml_f="22048" txt_i="13189" txt_f="13190">P</offsets></italic><offsets xml_i="22057" xml_f="22145" txt_i="13190" txt_f="13278">=1.00). However, normal bowel movement was reported by 36 (43.4%) of 83 patients in the </offsets><italic><offsets xml_i="22153" xml_f="22166" txt_i="13278" txt_f="13291">Lactobacillus</offsets></italic><offsets xml_i="22175" xml_f="22234" txt_i="13291" txt_f="13350"> group and 27 (30.3%) of 89 patients in the placebo group (</offsets><italic><offsets xml_i="22242" xml_f="22243" txt_i="13350" txt_f="13351">P</offsets></italic><offsets xml_i="22252" xml_f="22260" txt_i="13351" txt_f="13359">=0.10) (</offsets><xref ref-type="table" rid="T5"><offsets xml_i="22292" xml_f="22299" txt_i="13359" txt_f="13366">Table 5</offsets></xref><offsets xml_i="22306" xml_f="22359" txt_i="13366" txt_f="13419">). The results of multivariate analysis of the OR of </offsets><italic><offsets xml_i="22367" xml_f="22380" txt_i="13419" txt_f="13432">Lactobacillus</offsets></italic><offsets xml_i="22389" xml_f="22467" txt_i="13432" txt_f="13510"> for AAD-1, AAD-2, and change in bowel frequency and consistency are shown in </offsets><xref ref-type="table" rid="T6"><offsets xml_i="22499" xml_f="22506" txt_i="13510" txt_f="13517">Table 6</offsets></xref><offsets xml_i="22513" xml_f="22599" txt_i="13517" txt_f="13603">. The OR for no change in bowel frequency and consistency was 0.53 (95% CI 0.27-1.05, </offsets><italic><offsets xml_i="22607" xml_f="22608" txt_i="13603" txt_f="13604">P</offsets></italic><offsets xml_i="22617" xml_f="22624" txt_i="13604" txt_f="13611">=0.07).</offsets></p></sec><sec><title><offsets xml_i="22646" xml_f="22666" txt_i="13613" txt_f="13633">Risk factors for AAD</offsets></title><p><offsets xml_i="22677" xml_f="22781" txt_i="13634" txt_f="13738">The results of ITT analysis (n=214) of risk factors for AAD-1 (n=12) and non-AAD-1 (n=202) are shown in </offsets><xref ref-type="table" rid="T7"><offsets xml_i="22813" xml_f="22820" txt_i="13738" txt_f="13745">Table 7</offsets></xref><offsets xml_i="22827" xml_f="22908" txt_i="13745" txt_f="13826">. AAD-1 was more prevalent in patients with no medical illness (75.0% vs 40.6%) (</offsets><italic><offsets xml_i="22916" xml_f="22917" txt_i="13826" txt_f="13827">P</offsets></italic><offsets xml_i="22926" xml_f="23013" txt_i="13827" txt_f="13914">=0.04) and those with a longer duration of antibiotic use (13.8±2.0 vs 11.9±3.6 days) (</offsets><italic><offsets xml_i="23021" xml_f="23022" txt_i="13914" txt_f="13915">P</offsets></italic><offsets xml_i="23031" xml_f="23154" txt_i="13915" txt_f="14038">=0.01). There was also a tendency for AAD-1 patients to have greater baseline bowel movement (1.4±0.7 vs 1.0±0.4 per day) (</offsets><italic><offsets xml_i="23162" xml_f="23163" txt_i="14038" txt_f="14039">P</offsets></italic><offsets xml_i="23172" xml_f="23226" txt_i="14039" txt_f="14093">=0.08), remnant drugs (9.2±11.4 vs 3.6±7.5 capsules) (</offsets><italic><offsets xml_i="23234" xml_f="23235" txt_i="14093" txt_f="14094">P</offsets></italic><offsets xml_i="23244" xml_f="23299" txt_i="14094" txt_f="14149">=0.06) or to use β-lactam antibiotics (100% vs 75.7%) (</offsets><italic><offsets xml_i="23307" xml_f="23308" txt_i="14149" txt_f="14150">P</offsets></italic><offsets xml_i="23317" xml_f="23401" txt_i="14150" txt_f="14234">=0.07). AAD-2 was more prevalent in patients who were younger (53±16 vs 62 ±15 yr) (</offsets><italic><offsets xml_i="23409" xml_f="23410" txt_i="14234" txt_f="14235">P</offsets></italic><offsets xml_i="23419" xml_f="23468" txt_i="14235" txt_f="14284">=0.01), had no medical illness (68.0% vs 39.2%) (</offsets><italic><offsets xml_i="23476" xml_f="23477" txt_i="14284" txt_f="14285">P</offsets></italic><offsets xml_i="23486" xml_f="23565" txt_i="14285" txt_f="14364">=0.01) or had a longer duration of antibiotic use (13.5±1.8 vs 11.8±3.7 days) (</offsets><italic><offsets xml_i="23573" xml_f="23574" txt_i="14364" txt_f="14365">P</offsets></italic><offsets xml_i="23583" xml_f="23718" txt_i="14365" txt_f="14500">=0.01). In addition, patients who developed AAD-2 had a tendency to have greater baseline bowel movement (1.3±0.6 vs 1.0±0.4 per day) (</offsets><italic><offsets xml_i="23726" xml_f="23727" txt_i="14500" txt_f="14501">P</offsets></italic><offsets xml_i="23736" xml_f="23789" txt_i="14501" txt_f="14554">=0.05), remnant drugs (5.8±8.8 vs 3.7±7.7 capsules) (</offsets><italic><offsets xml_i="23797" xml_f="23798" txt_i="14554" txt_f="14555">P</offsets></italic><offsets xml_i="23807" xml_f="23864" txt_i="14555" txt_f="14612">=0.07), or to use β-lactam antibiotics (92.0% vs 75.1%) (</offsets><italic><offsets xml_i="23872" xml_f="23873" txt_i="14612" txt_f="14613">P</offsets></italic><offsets xml_i="23882" xml_f="23889" txt_i="14613" txt_f="14620">=0.10).</offsets></p><p><offsets xml_i="23896" xml_f="24002" txt_i="14621" txt_f="14727">The results of PP analysis (n=172) of the risk factors for AAD-1 (n=8) and non-AAD-1 (n=164) are shown in </offsets><xref ref-type="table" rid="T8"><offsets xml_i="24034" xml_f="24041" txt_i="14727" txt_f="14734">Table 8</offsets></xref><offsets xml_i="24048" xml_f="24122" txt_i="14734" txt_f="14808">. AAD-1 tended to occur in patients who were younger (50±19 vs 60±16 yr) (</offsets><italic><offsets xml_i="24130" xml_f="24131" txt_i="14808" txt_f="14809">P</offsets></italic><offsets xml_i="24140" xml_f="24218" txt_i="14809" txt_f="14887">=0.06), or had elevated baseline bowel movement (1.4±0.5 vs 1.0±0.4 per day) (</offsets><italic><offsets xml_i="24226" xml_f="24227" txt_i="14887" txt_f="14888">P</offsets></italic><offsets xml_i="24236" xml_f="24317" txt_i="14888" txt_f="14969">=0.05). AAD-2 was more prevalent in patients who were young (51±16 vs 61±16 yr) (</offsets><italic><offsets xml_i="24325" xml_f="24326" txt_i="14969" txt_f="14970">P</offsets></italic><offsets xml_i="24335" xml_f="24383" txt_i="14970" txt_f="15018">=0.01), had a medical illness (23.5% vs 58.7%) (</offsets><italic><offsets xml_i="24391" xml_f="24392" txt_i="15018" txt_f="15019">P</offsets></italic><offsets xml_i="24401" xml_f="24478" txt_i="15019" txt_f="15096">=0.01), had a longer duration of antibiotic use (13.6±1.9 vs 12.3±3.4 days) (</offsets><italic><offsets xml_i="24486" xml_f="24487" txt_i="15096" txt_f="15097">P</offsets></italic><offsets xml_i="24496" xml_f="24548" txt_i="15097" txt_f="15149">=0.02) or use β-lactam antibiotics (100% vs 78.1%) (</offsets><italic><offsets xml_i="24556" xml_f="24557" txt_i="15149" txt_f="15150">P</offsets></italic><offsets xml_i="24566" xml_f="24697" txt_i="15150" txt_f="15281">=0.02). In addition, patients with AAD-2 had a tendency to have an increased baseline bowel movement (1.3±0.5 vs 1.0±0.4 per day) (</offsets><italic><offsets xml_i="24705" xml_f="24706" txt_i="15281" txt_f="15282">P</offsets></italic><offsets xml_i="24715" xml_f="24722" txt_i="15282" txt_f="15289">=0.06).</offsets></p></sec><sec><title><offsets xml_i="24744" xml_f="24758" txt_i="15291" txt_f="15305">Adverse events</offsets></title><p><offsets xml_i="24769" xml_f="24881" txt_i="15306" txt_f="15418">Mild abdominal discomfort was reported by 1 patient (0.9%) in the placebo group and by 3 patients (2.9%) in the </offsets><italic><offsets xml_i="24889" xml_f="24902" txt_i="15418" txt_f="15431">Lactobacillus</offsets></italic><offsets xml_i="24911" xml_f="24919" txt_i="15431" txt_f="15439"> group (</offsets><italic><offsets xml_i="24927" xml_f="24928" txt_i="15439" txt_f="15440">P</offsets></italic><offsets xml_i="24937" xml_f="25000" txt_i="15440" txt_f="15503">=0.35). Skin eruption was reported by 1 patient (0.97%) in the </offsets><italic><offsets xml_i="25008" xml_f="25021" txt_i="15503" txt_f="15516">Lactobacillus</offsets></italic><offsets xml_i="25030" xml_f="25130" txt_i="15516" txt_f="15616"> group. However, there were no significant adverse events associated with the use of Lacidofil® cap.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="25180" xml_f="25190" txt_i="15619" txt_f="15629">DISCUSSION</offsets></title><p><offsets xml_i="25201" xml_f="25240" txt_i="15630" txt_f="15669">This study evaluated the efficacy of a </offsets><italic><offsets xml_i="25248" xml_f="25261" txt_i="15669" txt_f="15682">Lactobacillus</offsets></italic><offsets xml_i="25270" xml_f="25516" txt_i="15682" txt_f="15928"> probiotic single-agent regimen for AAD. In our study, the number of AAD cases was not statistically different between the 2 groups and the prevalence of AAD was low (3.9-7.2%) compared with a previous report (2-25%) as assessed by ITT analysis (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="25547" xml_f="25548" txt_i="15928" txt_f="15929">2</offsets></xref><offsets xml_i="25555" xml_f="25697" txt_i="15929" txt_f="16071">). This result may be attributed to the short-term follow-up period because AAD may occur up to 2 months after stopping antibiotic treatment (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="25728" xml_f="25729" txt_i="16071" txt_f="16072">1</offsets></xref><offsets xml_i="25736" xml_f="25903" txt_i="16072" txt_f="16239">). Recent meta-analysis of 10 randomized, blinded, placebo-controlled trials showed that the combined risk ratio (RR) of developing AAD was significantly lower in the </offsets><italic><offsets xml_i="25911" xml_f="25924" txt_i="16239" txt_f="16252">Lactobacillus</offsets></italic><offsets xml_i="25933" xml_f="25996" txt_i="16252" txt_f="16315"> groups than in the placebo group (RR 0.35, 95% CI 0.19-0.67) (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="26028" xml_f="26030" txt_i="16315" txt_f="16317">19</offsets></xref><offsets xml_i="26037" xml_f="26249" txt_i="16317" txt_f="16529">). Large differences exist among trials, including our study. The indications for antibiotic therapy differed among the studies and included respiratory tract infection, otitis media, urinary tract infection and </offsets><italic><offsets xml_i="26257" xml_f="26276" txt_i="16529" txt_f="16548">Helicobacter pylori</offsets></italic><offsets xml_i="26285" xml_f="26297" txt_i="16548" txt_f="16560"> infection (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="26329" xml_f="26331" txt_i="16560" txt_f="16562">19</offsets></xref><offsets xml_i="26338" xml_f="26340" txt_i="16562" txt_f="16564">).</offsets></p><p><offsets xml_i="26347" xml_f="26393" txt_i="16565" txt_f="16611">According to a previous report, doses used in </offsets><italic><offsets xml_i="26401" xml_f="26414" txt_i="16611" txt_f="16624">Lactobacillus</offsets></italic><offsets xml_i="26423" xml_f="26448" txt_i="16624" txt_f="16649"> regimens range from 2×10</offsets><sup><offsets xml_i="26453" xml_f="26454" txt_i="16649" txt_f="16650">9</offsets></sup><offsets xml_i="26460" xml_f="26468" txt_i="16650" txt_f="16658"> to 4×10</offsets><sup><offsets xml_i="26473" xml_f="26475" txt_i="16658" txt_f="16660">10</offsets></sup><offsets xml_i="26481" xml_f="26512" txt_i="16660" txt_f="16691"> colony-forming units per day (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="26544" xml_f="26546" txt_i="16691" txt_f="16693">19</offsets></xref><offsets xml_i="26553" xml_f="26684" txt_i="16693" txt_f="16824">). There was considerable variation in the probiotic regimens used. It has been suggested that doses of probiotics should exceed 10</offsets><sup><offsets xml_i="26689" xml_f="26691" txt_i="16824" txt_f="16826">10</offsets></sup><offsets xml_i="26697" xml_f="26728" txt_i="16826" txt_f="16857"> colony-forming units per day (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="26760" xml_f="26762" txt_i="16857" txt_f="16859">10</offsets></xref><offsets xml_i="26769" xml_f="26802" txt_i="16859" txt_f="16892">). In our study, the dose of the </offsets><italic><offsets xml_i="26810" xml_f="26823" txt_i="16892" txt_f="16905">Lactobacillus</offsets></italic><offsets xml_i="26832" xml_f="26849" txt_i="16905" txt_f="16922"> regimen was 4×10</offsets><sup><offsets xml_i="26854" xml_f="26855" txt_i="16922" txt_f="16923">9</offsets></sup><offsets xml_i="26861" xml_f="26915" txt_i="16923" txt_f="16977"> colony-forming units. This may be the reason why the </offsets><italic><offsets xml_i="26923" xml_f="26936" txt_i="16977" txt_f="16990">Lactobacillus</offsets></italic><offsets xml_i="26945" xml_f="27071" txt_i="16990" txt_f="17113"> group preparation did not exhibit a protective effect for AAD. Thus, it is expected that if the does had been greater (&gt;10</offsets><sup><offsets xml_i="27076" xml_f="27078" txt_i="17113" txt_f="17115">10</offsets></sup><offsets xml_i="27084" xml_f="27321" txt_i="17115" txt_f="17352"> colony-forming units per day), it may have had a preventive effect on AAD. The effects of increasing dosages of probiotics should be monitored, irrespective of whether adverse events are expected. Further evaluations using standardized </offsets><italic><offsets xml_i="27329" xml_f="27342" txt_i="17352" txt_f="17365">Lactobacillus</offsets></italic><offsets xml_i="27351" xml_f="27392" txt_i="17365" txt_f="17406"> dosage forms and regimens are warranted.</offsets></p><p><offsets xml_i="27399" xml_f="27900" txt_i="17407" txt_f="17908">AAD was defined as loose or watery stools more than 3 times per day for at least 2 days. This stringent definition enabled us to differentiate between clinically relevant and clinically unimportant changes in the consistency of stools. The secondary outcome, AAD-2, was defined as loose or watery stools more than 2 times per day for at least 2 days. However, definitions of AAD vary between published studies. For example, Vanderhoof et al. defined diarrhea as ≥2 liquid stools per 24 hr on ≥2 days (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="27932" xml_f="27934" txt_i="17908" txt_f="17910">13</offsets></xref><offsets xml_i="27941" xml_f="28245" txt_i="17910" txt_f="18214">). Bowel frequency and consistency reflects bowel habits. Tables 3 and 4 showed that there were significant differences in bowel frequency and consistency. These results suggest that maintenance of usual bowel habit was promoted by the probiotic. This result is consistent with that of a previous trial (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="28277" xml_f="28279" txt_i="18214" txt_f="18216">20</offsets></xref><offsets xml_i="28286" xml_f="28418" txt_i="18216" txt_f="18348">) performed on children. Although the overall incidence of diarrhea was surprisingly low and the administration of a combination of </offsets><italic><offsets xml_i="28426" xml_f="28448" txt_i="18348" txt_f="18370">Bifidobacterium longum</offsets></italic><offsets xml_i="28457" xml_f="28464" txt_i="18370" txt_f="18377"> PL03, </offsets><italic><offsets xml_i="28472" xml_f="28484" txt_i="18377" txt_f="18389">L. rhamnosus</offsets></italic><offsets xml_i="28493" xml_f="28505" txt_i="18389" txt_f="18401"> KL53A, and </offsets><italic><offsets xml_i="28513" xml_f="28525" txt_i="18401" txt_f="18413">L. plantarum</offsets></italic><offsets xml_i="28534" xml_f="28637" txt_i="18413" txt_f="18516"> PL02 did not significantly alter the incidence of diarrhea, it reduced the daily frequency of stools (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="28669" xml_f="28671" txt_i="18516" txt_f="18518">20</offsets></xref><offsets xml_i="28678" xml_f="28680" txt_i="18518" txt_f="18520">).</offsets></p><p><offsets xml_i="28687" xml_f="29461" txt_i="18521" txt_f="19295">In our study, ITT (n=214) analysis gave better results than PP (n=172) analysis. Forty-two patients did not complete the study. Thus, the number of patients enrolled was less than that required to achieve the target statistical power for the PP analysis. Studies involving larger numbers of patients are necessary. Regarding risk factors, patients who had elevated baseline bowel movements, more remnant drugs, and greater use of β-lactam antibiotics had higher incidences of AAD-1 and AAD-2. These results show that patients with elevated bowel movement and low drug compliance had a higher incidence of AAD. However, increased bowel movements may have affected the underlying risk for development of AAD or their response to the probiotic. Thus, for analysis of the OR of </offsets><italic><offsets xml_i="29469" xml_f="29482" txt_i="19295" txt_f="19308">Lactobacillus</offsets></italic><offsets xml_i="29491" xml_f="29493" txt_i="19308" txt_f="19310"> (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="29525" xml_f="29533" txt_i="19310" txt_f="19318">Tables 4</offsets></xref><offsets xml_i="29540" xml_f="29542" txt_i="19318" txt_f="19320">, </offsets><xref ref-type="table" rid="T6"><offsets xml_i="29574" xml_f="29575" txt_i="19320" txt_f="19321">6</offsets></xref><offsets xml_i="29582" xml_f="29837" txt_i="19321" txt_f="19576">), we adjusted the data for baseline bowel movement and other confounding factors (age, medical illness, duration of total antibiotic use, and remnant drugs). β-lactam antibiotics, including penicillin and cephalosporins, are proven risk factors for AAD (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="29868" xml_f="29869" txt_i="19576" txt_f="19577">1</offsets></xref><offsets xml_i="29876" xml_f="30070" txt_i="19577" txt_f="19771">). In addition, AAD was more prevalent in subjects who were young, had no medical illness and had used antibiotics for a long period. Our result is not in accord with that of a previous report (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="30101" xml_f="30102" txt_i="19771" txt_f="19772">1</offsets></xref><offsets xml_i="30109" xml_f="30167" txt_i="19772" txt_f="19830">). The reason for this may be selection bias in our study.</offsets></p><p><italic><offsets xml_i="30182" xml_f="30194" txt_i="19831" txt_f="19843">L. rhamnosus</offsets></italic><offsets xml_i="30203" xml_f="30272" txt_i="19843" txt_f="19912"> has inhibitory activity against a wide range of bacteria, including </offsets><italic><offsets xml_i="30280" xml_f="30292" txt_i="19912" txt_f="19924">C. difficile</offsets></italic><offsets xml_i="30301" xml_f="30303" txt_i="19924" txt_f="19926"> (</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="30335" xml_f="30337" txt_i="19926" txt_f="19928">21</offsets></xref><offsets xml_i="30344" xml_f="30360" txt_i="19928" txt_f="19944">). In addition, </offsets><italic><offsets xml_i="30368" xml_f="30380" txt_i="19944" txt_f="19956">L. rhamnosus</offsets></italic><offsets xml_i="30389" xml_f="30545" txt_i="19956" txt_f="20112"> is expected to be useful for the prevention of AAD because it survives the digestive process and is not killed by the acidic pH of the stomach or by bile (</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="30577" xml_f="30579" txt_i="20112" txt_f="20114">22</offsets></xref><offsets xml_i="30586" xml_f="30620" txt_i="20114" txt_f="20148">). When administered exogenously, </offsets><italic><offsets xml_i="30628" xml_f="30640" txt_i="20148" txt_f="20160">L. rhamnosus</offsets></italic><offsets xml_i="30649" xml_f="30769" txt_i="20160" txt_f="20280"> persists in the colon for at least a week and modifies the colonic environment with potential positive health effects (</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="30801" xml_f="30803" txt_i="20280" txt_f="20282">23</offsets></xref><offsets xml_i="30810" xml_f="30812" txt_i="20282" txt_f="20284">, </offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="30844" xml_f="30846" txt_i="20284" txt_f="20286">24</offsets></xref><offsets xml_i="30853" xml_f="30884" txt_i="20286" txt_f="20317">). There are 3 reports showing </offsets><italic><offsets xml_i="30892" xml_f="30904" txt_i="20317" txt_f="20329">L. rhamnosus</offsets></italic><offsets xml_i="30913" xml_f="30940" txt_i="20329" txt_f="20356"> prevents AAD in children (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="30972" xml_f="30974" txt_i="20356" txt_f="20358">12</offsets></xref><offsets xml_i="30981" xml_f="30982" txt_i="20358" txt_f="20359">-</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="31014" xml_f="31016" txt_i="20359" txt_f="20361">14</offsets></xref><offsets xml_i="31023" xml_f="31105" txt_i="20361" txt_f="20443">). For adults, 2 reports have been published concerning the synergistic effect of </offsets><italic><offsets xml_i="31113" xml_f="31125" txt_i="20443" txt_f="20455">L. rhamnosus</offsets></italic><offsets xml_i="31134" xml_f="31145" txt_i="20455" txt_f="20466"> with anti-</offsets><italic><offsets xml_i="31153" xml_f="31162" txt_i="20466" txt_f="20475">H. pylori</offsets></italic><offsets xml_i="31171" xml_f="31193" txt_i="20475" txt_f="20497"> eradication therapy (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="31225" xml_f="31227" txt_i="20497" txt_f="20499">11</offsets></xref><offsets xml_i="31234" xml_f="31236" txt_i="20499" txt_f="20501">, </offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="31268" xml_f="31270" txt_i="20501" txt_f="20503">16</offsets></xref><offsets xml_i="31277" xml_f="31479" txt_i="20503" txt_f="20705">). The rationale for the use of probiotics is that the use of antibiotics may result in a disturbance of the normal intestinal microflora, which is one of the key factors in the pathogenesis of AAD and </offsets><italic><offsets xml_i="31487" xml_f="31499" txt_i="20705" txt_f="20717">C. difficile</offsets></italic><offsets xml_i="31508" xml_f="31520" txt_i="20717" txt_f="20729"> infection (</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="31552" xml_f="31554" txt_i="20729" txt_f="20731">25</offsets></xref><offsets xml_i="31561" xml_f="31633" txt_i="20731" txt_f="20803">). There are several possible mechanisms by which probiotics, including </offsets><italic><offsets xml_i="31641" xml_f="31654" txt_i="20803" txt_f="20816">Lactobacillus</offsets></italic><offsets xml_i="31663" xml_f="31757" txt_i="20816" txt_f="20910">, exert preventative effects on AAD. These include the synthesis of antimicrobial substances (</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="31789" xml_f="31791" txt_i="20910" txt_f="20912">17</offsets></xref><offsets xml_i="31798" xml_f="31800" txt_i="20912" txt_f="20914">, </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="31832" xml_f="31834" txt_i="20914" txt_f="20916">22</offsets></xref><offsets xml_i="31841" xml_f="31843" txt_i="20916" txt_f="20918">, </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="31875" xml_f="31877" txt_i="20918" txt_f="20920">26</offsets></xref><offsets xml_i="31884" xml_f="32047" txt_i="20920" txt_f="21083">), competition for nutrients required for the growth of pathogens, competitive inhibition of adhesion of pathogens, and modification of toxins or toxin receptors (</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="32079" xml_f="32081" txt_i="21083" txt_f="21085">27</offsets></xref><offsets xml_i="32088" xml_f="32090" txt_i="21085" txt_f="21087">).</offsets></p><p><xref ref-type="bibr" rid="B10"><offsets xml_i="32129" xml_f="32131" txt_i="21088" txt_f="21090">10</offsets></xref><offsets xml_i="32138" xml_f="32213" txt_i="21090" txt_f="21165">). Although bacteremia and fungemia have been reported in the literatures (</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="32245" xml_f="32247" txt_i="21165" txt_f="21167">28</offsets></xref><offsets xml_i="32254" xml_f="32256" txt_i="21167" txt_f="21169">, </offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="32288" xml_f="32290" txt_i="21169" txt_f="21171">29</offsets></xref><offsets xml_i="32297" xml_f="32603" txt_i="21171" txt_f="21477">), our study showed only mild abdominal discomfort in 1 patient and skin eruption in 3 patients without any significant adverse events. Caution should be exercised for patients who are severely ill and are receiving nutrition or antibiotics through a potentially open portal catheter or a nasogastric tube.</offsets></p><p><offsets xml_i="32610" xml_f="32866" txt_i="21478" txt_f="21734">Our study had some limitations. First, the incidence of AAD was much lower in our study than in previous studies. Our patients were followed up for only 2 weeks after antibiotic therapy. As AAD can occur up to 2 months after stopping antibiotic treatment (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="32897" xml_f="32898" txt_i="21734" txt_f="21735">1</offsets></xref><offsets xml_i="32905" xml_f="33699" txt_i="21735" txt_f="22529">), some cases might have been missed. Second, the patients were not normally distributed. Some centers recruited more patients than allocated, and others had fewer cases. This imbalance was caused by differences in the hospital size and location, and the incidence of antibiotic-naïve respiratory infections at the hospitals. Third, the difference between hospitals in the main antibiotic prescribed is a potential weakness because the incidence of AAD differs between groups of antibiotics. However, there was no significant difference in antibiotic use between the 2 groups. Finally, although the required sample size was 220, we performed the study using 214 patients. The most frequent limitation of previous studies may also have been insufficient power to detect significant differences (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="33731" xml_f="33733" txt_i="22529" txt_f="22531">19</offsets></xref><offsets xml_i="33740" xml_f="33917" txt_i="22531" txt_f="22708">). Few investigators have calculated required sample sizes, and 3 investigators reported that slow recruitment of study patients resulted in premature termination of the trial (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="33949" xml_f="33951" txt_i="22708" txt_f="22710">10</offsets></xref><offsets xml_i="33958" xml_f="33960" txt_i="22710" txt_f="22712">, </offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="33992" xml_f="33994" txt_i="22712" txt_f="22714">30</offsets></xref><offsets xml_i="34001" xml_f="34130" txt_i="22714" txt_f="22843">). However, our study has value as the first prospective, randomized, double-blind, multicenter study on the effect of probiotic </offsets><italic><offsets xml_i="34138" xml_f="34151" txt_i="22843" txt_f="22856">Lactobacillus</offsets></italic><offsets xml_i="34160" xml_f="34196" txt_i="22856" txt_f="22892"> for the prevention of AAD in Korea.</offsets></p><p><offsets xml_i="34203" xml_f="34363" txt_i="22893" txt_f="23053">In conclusion, although Lacidofil® cap does not reduce the occurrence of AAD in adult patients with respiratory tract infection who have taken antibiotics, the </offsets><italic><offsets xml_i="34371" xml_f="34384" txt_i="23053" txt_f="23066">Lactobacillus</offsets></italic><offsets xml_i="34393" xml_f="34511" txt_i="23066" txt_f="23184"> group maintains their bowel habits to a greater extent than the placebo group without any significant adverse events.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by the research fund of the Korean Association for the Study of Intestinal Diseases. There was no conflict of interest between the Lacidofil® cap pharmaceutical company (Pharmbio Korea Co., Ltd.) and this study.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>Epidemiology, risk factors and treatments for antibiotic-associated diarrhea</article-title><source>Dig Dis</source><year>1998</year><volume>16</volume><fpage>292</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">9892789</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name></person-group><article-title>Clinical practice. Antibiotic-associated diarrhea</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">11821511</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>G</given-names></name><name><surname>Thomalla</surname><given-names>S</given-names></name><name><surname>Ackermann</surname><given-names>F</given-names></name><name><surname>Schaumann</surname><given-names>R</given-names></name><name><surname>Rodloff</surname><given-names>AC</given-names></name><name><surname>Ruf</surname><given-names>BR</given-names></name></person-group><article-title>Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea</article-title><source>J Med Microbiol</source><year>2005</year><volume>54</volume><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">15673508</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>Normal flora: diversity and functions</article-title><source>Microb Ecol Health Dis</source><year>2000</year><volume>12</volume><fpage>193</fpage><lpage>207</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>A review of the evidence of health claims for biotherapeutic agents</article-title><source>Microb Ecol Health Dis</source><year>2000</year><volume>12</volume><fpage>65</fpage><lpage>76</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qamar</surname><given-names>A</given-names></name><name><surname>Aboudola</surname><given-names>S</given-names></name><name><surname>Warny</surname><given-names>M</given-names></name><name><surname>Michetti</surname><given-names>P</given-names></name><name><surname>Pothoulakis</surname><given-names>C</given-names></name><name><surname>LaMont</surname><given-names>JT</given-names></name><name><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><fpage>2762</fpage><lpage>2765</lpage><pub-id pub-id-type="pmid">11254650</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmer</surname><given-names>GW</given-names></name></person-group><article-title>Probiotics: "Living drugs"</article-title><source>Am J Health Syst Pharm</source><year>2001</year><volume>58</volume><fpage>1101</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">11449853</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pépin</surname><given-names>J</given-names></name><name><surname>Valiquette</surname><given-names>L</given-names></name><name><surname>Alary</surname><given-names>ME</given-names></name><name><surname>Villemure</surname><given-names>P</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Forget</surname><given-names>K</given-names></name><name><surname>Pépin</surname><given-names>K</given-names></name><name><surname>Chouinard</surname><given-names>D</given-names></name></person-group><article-title>Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease activity</article-title><source>CMAJ</source><year>2004</year><volume>171</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">15337727</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katikireddi</surname><given-names>V</given-names></name></person-group><article-title>UK launches inquired into Clostridium difficile outbreak</article-title><source>CMAJ</source><year>2005</year><volume>173</volume><fpage>138</fpage><pub-id pub-id-type="pmid">16027424</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>812</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">16635227</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Di Caro</surname><given-names>S</given-names></name><name><surname>Covino</surname><given-names>M</given-names></name><name><surname>Armuzzi</surname><given-names>A</given-names></name><name><surname>Gabrielli</surname><given-names>M</given-names></name><name><surname>Santarelli</surname><given-names>L</given-names></name><name><surname>Nista</surname><given-names>EC</given-names></name><name><surname>Cammarota</surname><given-names>G</given-names></name><name><surname>Gasbarrini</surname><given-names>G</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name></person-group><article-title>Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study</article-title><source>Am J Gastroenterol</source><year>2002</year><volume>97</volume><fpage>2744</fpage><lpage>2749</lpage><pub-id pub-id-type="pmid">12425542</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvola</surname><given-names>T</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>Torkkeli</surname><given-names>S</given-names></name><name><surname>Mykkänen</surname><given-names>H</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Maunula</surname><given-names>L</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name></person-group><article-title>Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study</article-title><source>Pediatrics</source><year>1999</year><volume>104</volume><fpage>e64</fpage><pub-id pub-id-type="pmid">10545590</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderhoof</surname><given-names>JA</given-names></name><name><surname>Whitney</surname><given-names>DB</given-names></name><name><surname>Antonson</surname><given-names>DL</given-names></name><name><surname>Hanner</surname><given-names>TL</given-names></name><name><surname>Lupo</surname><given-names>JV</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name></person-group><article-title>Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children</article-title><source>J Pediatr</source><year>1999</year><volume>135</volume><fpage>564</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">10547243</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Kotowska</surname><given-names>M</given-names></name><name><surname>Mrukowicz</surname><given-names>JZ</given-names></name><name><surname>Armańska</surname><given-names>M</given-names></name><name><surname>Mikołajczyk</surname><given-names>W</given-names></name></person-group><article-title>Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants</article-title><source>J Pediatr</source><year>2001</year><volume>138</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11241043</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MR</given-names></name><name><surname>Litin</surname><given-names>SC</given-names></name><name><surname>Osmon</surname><given-names>DR</given-names></name><name><surname>Corr</surname><given-names>AP</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name></person-group><article-title>Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial</article-title><source>Mayo Clin Proc</source><year>2001</year><volume>76</volume><fpage>883</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">11560298</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armuzzi</surname><given-names>A</given-names></name><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Ojetti</surname><given-names>V</given-names></name><name><surname>Bartolozzi</surname><given-names>F</given-names></name><name><surname>Canducci</surname><given-names>F</given-names></name><name><surname>Candelli</surname><given-names>M</given-names></name><name><surname>Santarelli</surname><given-names>L</given-names></name><name><surname>Cammarota</surname><given-names>G</given-names></name><name><surname>De Lorenzo</surname><given-names>A</given-names></name><name><surname>Pola</surname><given-names>P</given-names></name><name><surname>Gasbarrini</surname><given-names>G</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name></person-group><article-title>Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study</article-title><source>Digestion</source><year>2001</year><volume>63</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11173893</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beausoleil</surname><given-names>M</given-names></name><name><surname>Fortier</surname><given-names>N</given-names></name><name><surname>Guénette</surname><given-names>S</given-names></name><name><surname>L'ecuyer</surname><given-names>A</given-names></name><name><surname>Savoie</surname><given-names>M</given-names></name><name><surname>Franco</surname><given-names>M</given-names></name><name><surname>Lachaine</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>K</given-names></name></person-group><article-title>Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial</article-title><source>Can J Gastroenterol</source><year>2007</year><volume>21</volume><fpage>732</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">18026577</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickson</surname><given-names>M</given-names></name><name><surname>D'Souza</surname><given-names>AL</given-names></name><name><surname>Muthu</surname><given-names>N</given-names></name><name><surname>Rogers</surname><given-names>TR</given-names></name><name><surname>Want</surname><given-names>S</given-names></name><name><surname>Rajkumar</surname><given-names>C</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name></person-group><article-title>Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial</article-title><source>BMJ</source><year>2007</year><volume>335</volume><fpage>80</fpage><pub-id pub-id-type="pmid">17604300</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale-Pradhan</surname><given-names>PB</given-names></name><name><surname>Jassal</surname><given-names>HK</given-names></name><name><surname>Wilhelm</surname><given-names>SM</given-names></name></person-group><article-title>Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis</article-title><source>Pharmacotherapy</source><year>2010</year><volume>30</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">20099986</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szymański</surname><given-names>H</given-names></name><name><surname>Armańska</surname><given-names>M</given-names></name><name><surname>Kowalska-Duplaga</surname><given-names>K</given-names></name><name><surname>Szajewska</surname><given-names>H</given-names></name></person-group><article-title>Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial</article-title><source>Digestion</source><year>2008</year><volume>78</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">18701826</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Jacobus</surname><given-names>NV</given-names></name><name><surname>Deneke</surname><given-names>C</given-names></name><name><surname>Gorbach</surname><given-names>SL</given-names></name></person-group><article-title>Antimicrobial substance from a human Lactobacillus strain</article-title><source>Antimicrob Agents Chemother</source><year>1987</year><volume>31</volume><fpage>1231</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">3307619</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alander</surname><given-names>M</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name><name><surname>Saxelin</surname><given-names>M</given-names></name><name><surname>Vilpponen-Salmela</surname><given-names>T</given-names></name><name><surname>Mattila-Sandholm</surname><given-names>T</given-names></name><name><surname>von Wright</surname><given-names>A</given-names></name></person-group><article-title>Recovery of Lactobacillus rhamnosus GG from human colonic biopsies</article-title><source>Lett Appl Microbiol</source><year>1997</year><volume>24</volume><fpage>361</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">9172443</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldin</surname><given-names>BR</given-names></name><name><surname>Gorbach</surname><given-names>SL</given-names></name><name><surname>Saxelin</surname><given-names>M</given-names></name><name><surname>Barakat</surname><given-names>S</given-names></name><name><surname>Gualtieri</surname><given-names>L</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name></person-group><article-title>Survival of Lactobacillus species (strain GG) in human gastrointestinal tract</article-title><source>Dig Dis Sci</source><year>1992</year><volume>37</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">1728516</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>WH</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name><name><surname>Mykkänen</surname><given-names>H</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Hänninen</surname><given-names>O</given-names></name></person-group><article-title>Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults</article-title><source>J Nutr</source><year>1994</year><volume>124</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">8283290</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surawicz</surname><given-names>CM</given-names></name><name><surname>Elmer</surname><given-names>GW</given-names></name><name><surname>Speelman</surname><given-names>P</given-names></name><name><surname>McFarland</surname><given-names>LV</given-names></name><name><surname>Chinn</surname><given-names>J</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name></person-group><article-title>Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective-study</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">2494098</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coconnier</surname><given-names>MH</given-names></name><name><surname>Liévin</surname><given-names>V</given-names></name><name><surname>Bernet-Camard</surname><given-names>MF</given-names></name><name><surname>Hudault</surname><given-names>S</given-names></name><name><surname>Servin</surname><given-names>AL</given-names></name></person-group><article-title>Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB</article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><fpage>1046</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">9145867</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruszczyński</surname><given-names>M</given-names></name><name><surname>Radzikowski</surname><given-names>A</given-names></name><name><surname>Szajewska</surname><given-names>H</given-names></name></person-group><article-title>Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>28</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">18410562</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Groote</surname><given-names>MA</given-names></name><name><surname>Frank</surname><given-names>DN</given-names></name><name><surname>Dowell</surname><given-names>E</given-names></name><name><surname>Glode</surname><given-names>MP</given-names></name><name><surname>Pace</surname><given-names>NR</given-names></name></person-group><article-title>Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome</article-title><source>Pediatr Infect Dis J</source><year>2005</year><volume>24</volume><fpage>278</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">15750472</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>RJ</given-names></name><name><surname>Vanderhoof</surname><given-names>JA</given-names></name></person-group><article-title>Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2004</year><volume>39</volume><fpage>436</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">15448440</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jirapinyo</surname><given-names>P</given-names></name><name><surname>Densupsoontorn</surname><given-names>N</given-names></name><name><surname>Thamonsiri</surname><given-names>N</given-names></name><name><surname>Wongarn</surname><given-names>R</given-names></name></person-group><article-title>Prevention of antibiotic-associated diarrhea in infants by probiotics</article-title><source>J Med Assoc Thai</source><year>2002</year><volume>85</volume><issue>Suppl 2</issue><fpage>S739</fpage><lpage>S742</lpage><pub-id pub-id-type="pmid">12403254</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Patient flow diagram.</p></caption><graphic xlink:href="jkms-25-1784-g001"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study patients</p></caption><graphic xlink:href="jkms-25-1784-i001"></graphic><table-wrap-foot><fn><p><sup>*</sup>χ<sup>2</sup> or Fisher exact test.</p><p>BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Antibiotics use in the placebo and the Lactobacillus groups</p></caption><graphic xlink:href="jkms-25-1784-i002"></graphic><table-wrap-foot><fn><p><sup>*</sup>Cephalosporins plus penicillin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of AAD between the placebo and the Lactobacillus groups (ITT analysis, n=214)</p></caption><graphic xlink:href="jkms-25-1784-i003"></graphic></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Odds ratio of <italic>Lactobacillus</italic> (ITT analysis, n=214)</p></caption><graphic xlink:href="jkms-25-1784-i004"></graphic><table-wrap-foot><fn><p><sup>*</sup>Logistic analysis: adjusted for age, baseline bowel movement, medical illness, duration of total antibiotic use, and remnant drugs.</p><p>CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Comparison of AAD between the placebo and the <italic>Lactobacillus</italic> groups (PP analysis, n=172)</p></caption><graphic xlink:href="jkms-25-1784-i005"></graphic></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Odds ratio of <italic>Lactobacillus</italic> (PP analysis, n=172)</p></caption><graphic xlink:href="jkms-25-1784-i006"></graphic><table-wrap-foot><fn><p><sup>*</sup>Logistic analysis: adjusted for age, baseline bowel movement, medical illness, and duration of total antibiotic use.</p><p>CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Risk factors for AAD (ITT analysis, n=214)</p></caption><graphic xlink:href="jkms-25-1784-i007"></graphic></table-wrap><table-wrap id="T8" position="float"><label>Table 8</label><caption><p>Risk factors for AAD (PP analysis, n=172)</p></caption><graphic xlink:href="jkms-25-1784-i008"></graphic></table-wrap></floats-group></article>